Works matching AU Eliasson, Erik

Results: 42

Bleeding and thromboembolism due to drug-drug interactions with non-vitamin K antagonist oral anticoagulants—a Swedish, register-based cohort study in atrial fibrillation outpatients.

Published in:

European Journal of Clinical Pharmacology, 2021, v. 77, n. 3, p. 409, doi. 10.1007/s00228-020-03015-7

By:

Holm, Johan;
Mannheimer, Buster;
Malmström, Rickard E;
Eliasson, Erik;
Lindh, Jonatan D

Publication type:

Article

A limited number of prescribed drugs account for the great majority of drug-drug interactions.

Published in:

European Journal of Clinical Pharmacology, 2014, v. 70, n. 11, p. 1375, doi. 10.1007/s00228-014-1745-3

By:

Holm, Johan;
Eiermann, Birgit;
Eliasson, Erik;
Mannheimer, Buster

Publication type:

Article

Risperidone metabolic ratio as a biomarker of individual CYP2D6 genotype in schizophrenic patients.

Published in:

European Journal of Clinical Pharmacology, 2014, v. 70, n. 6, p. 695, doi. 10.1007/s00228-014-1664-3

By:

Mannheimer, Buster;
Holm, Johan;
Koukel, Larissa;
Bertilsson, Leif;
Ösby, Urban;
Eliasson, Erik

Publication type:

Article

Therapeutic drug monitoring for tomorrow.

Published in:

European Journal of Clinical Pharmacology, 2013, v. 69, p. 25, doi. 10.1007/s00228-013-1504-x

By:

Eliasson, Erik;
Lindh, Jonatan;
Malmström, Rickard;
Beck, Olof;
Dahl, Marja-Liisa

Publication type:

Article

Carriers of the UGT1A4 142T>G gene variant are predisposed to reduced olanzapine exposure—an impact similar to male gender or smoking in schizophrenic patients.

Published in:

European Journal of Clinical Pharmacology, 2010, v. 66, n. 5, p. 465, doi. 10.1007/s00228-009-0783-8

By:

Ghotbi, Roza;
Mannheimer, Buster;
Aklillu, Eleni;
Suda, Akira;
Bertilsson, Leif;
Eliasson, Erik;
Ösby, Urban

Publication type:

Article

Severely diminished response to vitamin K-treatment for self-inflicted warfarin intoxication in a patient genotyped as CYP2C933.

Published in:

2009

By:

Bäckström, Tobias;
Barkman, Gunilla;
Lindh, Jonatan D.;
Eliasson, Erik

Publication type:

Letter

Kinetics of omeprazole and escitalopram in relation to the CYP2C19*17 allele in healthy subjects.

Published in:

European Journal of Clinical Pharmacology, 2008, v. 64, n. 12, p. 1175, doi. 10.1007/s00228-008-0529-z

By:

Rosenborg, Staffan Ohlsson;
Mwinyi, Jessica;
Andersson, Maria;
Baldwin, R. Michael;
Pedersen, Rasmus Steen;
Sim, Sarah C.;
Bertilsson, Leif;
Ingelman-Sundberg, Magnus;
Eliasson, Erik

Publication type:

Article

CYP2C9 genetic variants and losartan oxidation in a Turkish population.

Published in:

European Journal of Clinical Pharmacology, 2004, v. 60, n. 5, p. 337, doi. 10.1007/s00228-004-0785-5

By:

Babaoglu, Melih O.;
Yasar, Umit;
Sandberg, Mia;
Eliasson, Erik;
Dahl, Marja-Liisa;
Kayaalp, S. Oguz;
Bozkurt, Atila

Publication type:

Article

Bioactivation of cyclophosphamide: the role of polymorphic CYP2C enzymes.

Published in:

European Journal of Clinical Pharmacology, 2003, v. 59, n. 2, p. 103, doi. 10.1007/s00228-003-0590-6

By:

Griskevicius, Laimonas;
Yasar, Ümit;
Sandberg, Mia;
Hidestrand, Mats;
Eliasson, Erik;
Tybring, Gunnel;
Hassan, Moustapha;
Dahl, Marja-Liisa

Publication type:

Article

The role of CYP2C9 genotype in the metabolism of diclofenac in vivo and in vitro.

Published in:

European Journal of Clinical Pharmacology, 2001, v. 57, n. 10, p. 729, doi. 10.1007/s00228-001-0376-7

By:

Yasar, Ümit;
Eliasson, Erik;
Forslund-Bergengren, Cecilia;
Tybring, Gunnel;
Gadd, Malin;
Sjöqvist, Folke;
Dahl, Marja-Liisa

Publication type:

Article

A paradigm shift in pharmacogenomics: From candidate polymorphisms to comprehensive sequencing.

Published in:

Basic & Clinical Pharmacology & Toxicology, 2022, v. 131, n. 6, p. 452, doi. 10.1111/bcpt.13779

By:

Zhou, Yitian;
Koutsilieri, Stefania;
Eliasson, Erik;
Lauschke, Volker M.

Publication type:

Article

Angiotensin II Receptor Blockers Inhibit the Generation of Epoxyeicosatrienoic Acid from Arachidonic Acid in Recombinant CYP2C9, CYP2J2 and Human Liver Microsomes.

Published in:

Basic & Clinical Pharmacology & Toxicology, 2017, v. 121, n. 4, p. 239, doi. 10.1111/bcpt.12789

By:

Senda, Asuna;
Mukai, Yuji;
Hayakawa, Toru;
Kato, Yuka;
Eliasson, Erik;
Rane, Anders;
Toda, Takaki;
Inotsume, Nobuo

Publication type:

Article

Reply to 'Multiple and Opposite Effects of Angiotensin II Receptor Blockers on the Bioavailability of Epoxyeicosatrienoic Acids'.

Published in:

Basic & Clinical Pharmacology & Toxicology, 2017, v. 121, n. 4, p. 215, doi. 10.1111/bcpt.12811

By:

Senda, Asuna;
Mukai, Yuji;
Hayakawa, Toru;
Kato, Yuka;
Eliasson, Erik;
Rane, Anders;
Toda, Takaki;
Inotsume, Nobuo

Publication type:

Article

The Role of CYP2C8 and CYP2C9 Genotypes in Losartan-Dependent Inhibition of Paclitaxel Metabolism in Human Liver Microsomes.

Published in:

Basic & Clinical Pharmacology & Toxicology, 2016, v. 118, n. 6, p. 408, doi. 10.1111/bcpt.12520

By:

Mukai, Yuji;
Senda, Asuna;
Toda, Takaki;
Eliasson, Erik;
Rane, Anders;
Inotsume, Nobuo

Publication type:

Article

Drug−drug Interaction between Losartan and Paclitaxel in Human Liver Microsomes with Different CYP2C8 Genotypes.

Published in:

Basic & Clinical Pharmacology & Toxicology, 2015, v. 116, n. 6, p. 493, doi. 10.1111/bcpt.12355

By:

Mukai, Yuji;
Senda, Asuna;
Toda, Takaki;
Hayakawa, Toru;
Eliasson, Erik;
Rane, Anders;
Inotsume, Nobuo

Publication type:

Article

Plasma Levels of 25-Hydroxyvitamin D<sub>3</sub> and In Vivo Markers of Cytochrome P450 3 A Activity in Swedes and Koreans: Effects of a Genetic Polymorphism and Oral Contraceptives.

Published in:

Basic & Clinical Pharmacology & Toxicology, 2014, v. 115, n. 4, p. 366, doi. 10.1111/bcpt.12230

By:

Nylén, Hanna;
Björkhem‐Bergman, Linda;
Ekström, Lena;
Roh, Hyung‐Keun;
Bertilsson, Leif;
Eliasson, Erik;
Lindh, Jonatan D.;
Diczfalusy, Ulf

Publication type:

Article

Distribution of plasma concentrations of first-line anti-TB drugs and individual MICs: a prospective cohort study in a low endemic setting.

Published in:

2018

By:

Niward, Katarina;
Forsman, Lina Davies;
Bruchfeld, Judith;
Chryssanthou, Erja;
Carlström, Oskar;
Alomari, Teba;
Carlsson, Björn;
Pohanka, Anton;
Mansjö, Mikael;
Nordvall, Michaela Jonsson;
Davies Forsman, Lina;
Jonsson Nordvall, Michaela;
Johansson, Anders G;
Eliasson, Erik;
Werngren, Jim;
Paues, Jakob;
Simonsson, Ulrika S H;
Schön, Thomas

Publication type:

journal article

Correlation Between Serum Concentrations of N-Desmethylclozapine and Granulocyte Levels in Patients with Schizophrenia: A Retrospective Observational Study.

Published in:

2017

By:

Smith, Robert;
Haslemo, Tore;
Andreassen, Ole;
Eliasson, Erik;
Dahl, Marja-Liisa;
Spigset, Olav;
Molden, Espen;
Smith, Robert L;
Andreassen, Ole A

Publication type:

journal article

Development and clinical implementation of an LC-HRMS method for ivacaftor, lumacaftor, tezacaftor and elexacaftor in human plasma and breast milk.

Published in:

Analytical & Bioanalytical Chemistry, 2024, v. 416, n. 26, p. 5565, doi. 10.1007/s00216-024-05496-2

By:

Hansson, Anna B.;
Wadström, Hjalmar;
Eliasson, Erik;
Al Shakirchi, Mahasin;
de Monestrol, Isabelle;
Barclay, Victoria

Publication type:

Article

Beneficial vasoactive endothelial effects of fluvastatin: focus on prostacyclin and nitric oxide.

Published in:

Heart & Vessels, 2011, v. 26, n. 6, p. 628, doi. 10.1007/s00380-010-0097-x

By:

Skogastierna, Cristine;
Luksha, Leonid;
Kublickiene, Karolina;
Eliasson, Erik;
Rane, Anders;
Ekström, Lena

Publication type:

Article

Influence of endoxifen on mammographic density: results from the KARISMA-Tam trial.

Published in:

JNCI: Journal of the National Cancer Institute, 2025, v. 117, n. 4, p. 629, doi. 10.1093/jnci/djae280

By:

Hammarström, Mattias;
Gabrielson, Marike;
Bergqvist, Jenny;
Lundholm, Cecilia;
Crippa, Alessio;
Bäcklund, Magnus;
Wengström, Yvonne;
Borgquist, Signe;
Eliasson, Erik;
Eriksson, Mikael;
Tapia, José;
Czene, Kamila;
Hall, Per

Publication type:

Article

Global distribution of functionally important CYP2C9 alleles and their inferred metabolic consequences.

Published in:

Human Genomics, 2023, v. 17, n. 1, p. 1, doi. 10.1186/s40246-023-00461-z

By:

Zhou, Yitian;
Nevosadová, Lenka;
Eliasson, Erik;
Lauschke, Volker M.

Publication type:

Article

Adverse drug reactions causing hospitalization can be monitored from computerized medical records and thereby indicate the quality of drug utilization.

Published in:

Pharmacoepidemiology & Drug Safety, 2006, v. 15, n. 3, p. 179, doi. 10.1002/pds.1154

By:

von Euler, Mia;
Eliasson, Erik;
Öhlén, Gunnar;
Bergman, Ulf

Publication type:

Article

Tribute to Folke Sjöqvist, a Pioneer in Clinical Pharmacology.

Published in:

Clinical Pharmacology & Therapeutics, 2020, v. 108, n. 6, p. 1127, doi. 10.1002/cpt.1935

By:

Dahl, Marja‐Liisa;
Bergman, Ulf;
Bertilsson, Leif;
Eliasson, Erik;
Gustafsson, Lars L.;
Panagiotidis, Georgios;
Rane, Anders

Publication type:

Article

Reply.

Published in:

2006

By:

Eliasson, Erik;
Lundblad, Mia Sandberg

Publication type:

Letter

Accumulation of celecoxib with a 7-fold higher drug exposure in individuals homozygous for CYP2C9*3.

Published in:

2006

By:

Lundblad, Mia Sandberg;
Ohlsson, Staffan;
Johansson, Peter;
Lafolie, Pierre;
Eliasson, Erik

Publication type:

Letter

Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype<sup>*</sup>.

Published in:

Clinical Pharmacology & Therapeutics, 2002, v. 71, n. 1, p. 89, doi. 10.1067/mcp.2002.121216

By:

Yasar, Ümit;
Forslund-Bergengren, Cecilia;
Tybring, Gunnel;
Dorado, Pedro;
LLerena, Adrián;
Sjöqvist, Folke;
Eliasson, Erik;
Dahl, Marja-Liisa

Publication type:

Article

Impairment of endoxifen formation in tamoxifen‐treated premenopausal breast cancer patients carrying reduced‐function CYP2D6 alleles.

Published in:

British Journal of Clinical Pharmacology, 2021, v. 87, n. 3, p. 1243, doi. 10.1111/bcp.14500

By:

Thorén, Linda;
Lindh, Jonatan D.;
Ackehed, Gerd;
Kringen, Marianne Kristiansen;
Hall, Per;
Bergh, Jonas;
Molden, Espen;
Margolin, Sara;
Eliasson, Erik

Publication type:

Article

Individualised dosing algorithm and personalised treatment of high‐dose rifampicin for tuberculosis.

Published in:

British Journal of Clinical Pharmacology, 2019, v. 85, n. 10, p. 2341, doi. 10.1111/bcp.14048

By:

Svensson, Robin J.;
Niward, Katarina;
Davies Forsman, Lina;
Bruchfeld, Judith;
Paues, Jakob;
Eliasson, Erik;
Schön, Thomas;
Simonsson, Ulrika S.H.

Publication type:

Article

Significantly lower CYP2D6 metabolism measured as the O/N‐desmethylvenlafaxine metabolic ratio in carriers of CYP2D641 versus CYP2D69 or CYP2D6*10: a study on therapeutic drug monitoring data from 1003 genotyped Scandinavian patients.

Published in:

British Journal of Clinical Pharmacology, 2019, v. 85, n. 1, p. 194, doi. 10.1111/bcp.13788

By:

Haslemo, Tore;
Eliasson, Erik;
Jukić, Marin M.;
Ingelman‐Sundberg, Magnus;
Molden, Espen

Publication type:

Article

Nationwide drug-dispensing data reveal important differences in adherence to drug label recommendations on CYP2D6-dependent drug interactions.

Published in:

British Journal of Clinical Pharmacology, 2010, v. 69, n. 4, p. 411, doi. 10.1111/j.1365-2125.2009.03598.x

By:

Mannheimer, Buster;
Wettermark, Björn;
Lundberg, Michael;
Pettersson, Hans;
von Bahr, Christer;
Eliasson, Erik

Publication type:

Article

Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers.

Published in:

British Journal of Clinical Pharmacology, 2008, v. 65, n. 5, p. 767, doi. 10.1111/j.1365-2125.2008.03104.x

By:

Baldwin, R. Michael;
Ohlsson, Staffan;
Pedersen, Rasmus Steen;
Mwinyi, Jessica;
Ingelman-Sundberg, Magnus;
Eliasson, Erik;
Bertilsson, Leif

Publication type:

Article

Oxidation of celecoxib by polymorphic cytochrome P450 2C9 and alcohol dehydrogenase.

Published in:

British Journal of Clinical Pharmacology, 2002, v. 54, n. 4, p. 423, doi. 10.1046/j.1365-2125.2002.01660.x

By:

Sandberg, Mia;
Yasar, Ümit;
Strömberg, Patrik;
Höög, Jan-Olov;
Eliasson, Erik

Publication type:

Article

Intra-individual variability in urinary losartan oxidation ratio, an in vivo marker of CYP2C9activity.

Published in:

British Journal of Clinical Pharmacology, 2002, v. 54, n. 2, p. 183, doi. 10.1046/j.1365-2125.2002.01646.x

By:

Yasar, Ümit;
Dahl, Marja-Liisa;
Christensen, Magnus;
Eliasson, Erik

Publication type:

Article

First dose target attainment with extended infusion regimens of piperacillin and meropenem.

Published in:

Critical Care, 2025, v. 29, n. 1, p. 1, doi. 10.1186/s13054-025-05445-0

By:

Beijer, Gustaf;
Swartling, Maria;
Nielsen, Elisabet I.;
Breuer, Olof;
Giske, Christian G.;
Eliasson, Erik;
Petersson, Johan

Publication type:

Article

Effect of Aging on Brain Injury Prediction in Rotational Head Trauma—A Parameter Study with a Rat Finite Element Model.

Published in:

Traffic Injury Prevention, 2015, v. 16, p. S91, doi. 10.1080/15389588.2015.1021416

By:

Antona-Makoshi, Jacobo;
Eliasson, Erik;
Davidsson, Johan;
Ejima, Susumu;
Ono, Koshiro

Publication type:

Article

PharmFreq: a comprehensive atlas of ethnogeographic allelic variation in clinically important pharmacogenes.

Published in:

Nucleic Acids Research, 2025, v. 53, n. D1, p. D1498, doi. 10.1093/nar/gkae1016

By:

Tremmel, Roman;
Zhou, Yitian;
Camara, Mahamadou D;
Laarif, Sofiene;
Eliasson, Erik;
Lauschke, Volker M

Publication type:

Article

Low attainment to PK/PD-targets for β-lactams in a multi-center study on the first 72 h of treatment in ICU patients.

Published in:

Scientific Reports, 2022, v. 12, n. 1, p. 1, doi. 10.1038/s41598-022-25967-9

By:

Smekal, Anna-Karin;
Furebring, Mia;
Eliasson, Erik;
Lipcsey, Miklos

Publication type:

Article

Association of CYP2C9 genotypes leading to high enzyme activity and colorectal cancer risk.

Published in:

Carcinogenesis, 2002, v. 23, n. 4, p. 665, doi. 10.1093/carcin/23.4.665

By:

Yasar, Ümit;
Eliasson, Erik;
Dahl, Marja-Liisa

Publication type:

Article

Adherence to endocrine therapy in early breast cancer in relation to Cytochrome P450 2D6 genotype: a comparison between pharmacy dispensation data and medical records.

Published in:

Breast Cancer Research & Treatment, 2023, v. 198, n. 3, p. 499, doi. 10.1007/s10549-023-06887-2

By:

Thorén, Linda;
Margolin, Sara;
Eliasson, Erik;
Bergh, Jonas;
Lindh, Jonatan D.

Publication type:

Article

Impact of systemic adjuvant therapy and CYP2D6 activity on mammographic density in a cohort of tamoxifen-treated breast cancer patients.

Published in:

Breast Cancer Research & Treatment, 2021, v. 190, n. 3, p. 451, doi. 10.1007/s10549-021-06386-2

By:

Thorén, Linda;
Eriksson, Mikael;
Lindh, Jonatan D.;
Czene, Kamila;
Bergh, Jonas;
Eliasson, Erik;
Hall, Per;
Margolin, Sara

Publication type:

Article

Roles of Different CYP Enzymes in the Formation of Specific Fluvastatin Metabolites by Human Liver Microsomes.

Published in:

Basic & Clinical Pharmacology & Toxicology, 2009, v. 105, n. 5, p. 327, doi. 10.1111/j.1742-7843.2009.00453.x

By:

Toda, Takaki;
Eliasson, Erik;
Ask, Birgitta;
Inotsume, Nobuo;
Rane, Anders

Publication type:

Article